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Background: The aim of this study was to explore the effects of HCV co-infection on virological effectiveness and
on CD4+ T-cell recovery in patients with an early and sustained virological response after HAART.
Methods: We performed a longitudinal analysis of 3,262 patients from the MASTER cohort, who started HAART
from 2000 to 2008. Patients were stratified into 6 groups by HCV status and type of anchor class. The early
virological outcome was the achievement of HIV RNA <500 copies/ml 4–8 months after HAART initiation. Time to
virological response was also evaluated by Kaplan-Meier analysis. The main outcome measure of early
immunological response was the achievement of CD4+ T-cell increase by ≥100/mm3 from baseline to month 4–8
in virological responder patients. Late immunological outcome was absolute variation of CD4+ T-cell count with
respect to baseline up to month 24. Multivariable analysis (ANCOVA) investigated predictors for this outcome.
Results: The early virological response was higher in HCV Ab-negative than HCV Ab-positive patients prescribed PI/r
(92.2% versus 88%; p=0.01) or NNRTI (88.5% versus 84.7%; p=0.06). HCV Ab-positive serostatus was a significant predictor
of a delayed virological suppression independently from other variables, including types of anchor class. Reactivity for
HCV antibodies was associated with a lower probability of obtaining ≥100/mm3 CD4+ increase within 8 months from
HAART initiation in patients treated with PI/r (62.2% among HCV Ab-positive patients versus 70.9% among HCV Ab-
negative patients; p=0.003) and NNRTI (63.7% versus 74.7%; p< 0.001). Regarding late CD4+ increase, positive HCV Ab
appeared to impair immune reconstitution in terms of absolute CD4+ T-cell count increase both in patients treated with
PI/r (p=0.013) and in those treated with NNRTI (p=0.002). This was confirmed at a multivariable analysis up to 12 months
of follow-up.
Conclusions: In this large cohort, HCV Ab reactivity was associated with an inferior virological outcome and an
independent association between HCV Ab-positivity and smaller CD4+ increase was evident up to 12 months of follow-
up. Although the difference in CD4+ T-cell count was modest, a stricter follow-up and optimization of HAART strategy
appear to be important in HIV patients co-infected by HCV. Moreover, our data support anti-HCV treatment leading to
HCV eradication as a means to facilitate the achievement of the viro-immunological goals of HAART.
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The introduction of highly-active anti-retroviral therapy
(HAART) has determined a dramatic improvement in
the management of HIV-1 infection, leading to suppres-
sion of HIV viraemia and consequent restoration of the
immune function. However, viro-immunological effective-
ness of HAART may be hampered by other factors [1-4].
In particular, the impact of co-infection with hepatitis
C virus (HCV) on treatment response is still controver-
sial despite the large number of published data. In this
respect, co-infection with HCV has a potential great
relevance because its prevalence is up to 80% in those
who acquired HIV through injection drug use [5].
Several studies reported a reduced CD4+ T-cell count
recovery in patients with HIV and HCV co-infection with
respect to patients with HIV alone [6-13]. This conclusion
was further supported by a meta-analysis [14], but was not
confirmed by other results [15-17]. Moreover, variable
levels of HIV RNA may confound the association of HIV
co-infection with CD4+ T-cell count increase. In particu-
lar, we need data in patients who obtained early and sus-
tained virological response to minimize the influence of
variable levels of HIV replication on the immunological
response because the results currently available are incon-
sistent, with some studies demonstrating a difference [10]
and others disproving it [18,19].
Regarding virological response, several studies did not
demonstrate any significant associations with HCV sta-
tus [16,17], however one recent study evaluated time to
virological suppression as primary outcome and found
that HCV Ab-positivity was associated with a reduced
rate of virological suppression at bivariate analysis, but
not adjusting for history of intravenous drug use. [20].
The aim of this study was to explore the effects of HCV
co-infection on virological effectiveness and on CD4+ T-
cell reconstitution in patients with an early and sustained
virological response after HAART. Also, stratified analyses
were conducted by anchor drug --i.e. the antiretroviral
drug added as third component to a backbone of nucleo-
side reverse transcriptase inhibitors-- to explore whether
different drug characteristics may have an effect.
Methods
Design of the study and cohort used
We conducted an analysis on naïve patients enrolled in the
Italian MASTER (Management of standardized antiretro-
viral therapy) cohort who started first line HAART contain-
ing protease inhibitors (either boosted by ritonavir - PI/r -
or not boosted) or non-nucleoside reverse transcriptase
inhibitor (NNRTI) from 1st January 2000 to 31st December
2008. Patients were stratified into 6 groups according to the
type of anchor class received (PI, PI/r or NNRTI) and HCV
Ab status (positive or negative).The MASTER cohort is a longitudinal multicenter
cohort consisting of a general HIV patient population in
nine referral centres throughout Italy (http://www.master-
cohort.it). The distinguishing characteristic of this cohort
is that data are compiled in a common electronic chart
(Health & Notes 3.5W, Healthware S.p.A., Naples, Italy) in
use in the participating centres. Data are recorded over a
standardized time-scale every 3 months, with merging and
data cleaning performed at the coordinating centre every
6 months. Subjects gave written informed consent for par-
ticipation in the observational cohort, and each site
obtained approval by its Ethics Committee.
Study outcomes
Virological outcome
The main virological outcome was the achievement of
early virological response, i.e., HIV RNA <500 copies/ml
within 8 months from HAART initiation (values
included between 4 and 8 months, closest to month 8,
were considered). This limit of detection for undetect-
ability was chosen because it was the highest value ever
used in the clinical centers participating to the MASTER
cohort during the time frame of the study. The main
virological outcome was assessed both through intent-
to-treat (ITT) and on treatment (OT) analyses. At ITT
analysis, all patients were included even if they changed
drugs used as anchor (PI or PI/r to NNRTI and vice-
versa, or PI to PI/r and vice-versa); at OT analysis, only
patients who did not change class therapy were consid-
ered. A logistic model was performed with undetectable
HIV RNA as dependent variable and HIV RNA at base-
line and HCV Ab reactivity as independent variables.
We also assessed the rate of patients with HIV
RNA <500 copies/ml by Kaplan Meier survival curves
over a mean length of follow-up of 52 (SD: 33)
months.
Possible predictors of time to virological suppression
were assessed through Cox regression analysis considering
as independent variables either baseline factors (age at
HAART initiation, gender, risk factors for HIV acquisition,
history of AIDS diagnosis, HIV RNA, HCV Ab status, cal-
endar year at HAART) or time dependent factors (CD4+
T-cell count, type of anchor class). All the variables were
input in a multivariate model. The proportional hazards
assumption was checked by determining whether plotting
the log [−log(survival)] curve against survival time
resulted in parallel lines for each covariate. Moreover,
scaled Schoenfeld residuals were plotted on functions of
time and tested for a non-zero slope.
Immunological outcomes
For the study of early immunological response, we used
patients who obtained HIV RNA <500 copies/ml within
8 months from HAART initiation (values included
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dered) and CD4+ T-cell count was assessed in the same
time frame (values closest to month 8 were used). In these
patients, two immunological outcomes were evaluated: (i)
CD4+ T-cell increase by ≥100/mm3 from baseline (ca-
tegorical outcome); (ii) absolute CD4+ T-cell change (con-
tinuous outcome). For the categorical outcome, a bivariate
logistic analysis was performed with HIV RNA at baseline
and HCV Ab status (positive or negative) used as inde-
pendent variables. For the continuous outcome,
ANCOVA model was performed. In this analysis, CD4+
T-cell change from baseline was the dependent variable,
HIV RNA value at baseline was the covariate, and HCV
Ab reactivity was the fixed effect.
For the study of late immunological response, the
same patients were studied until HIV RNA remained
undetectable (<500 copies/ml), patients were lost to
follow-up (lack of exams for ≥6 months), or died. More-
over, analyses were truncated when <30% patients were
under observation to avoid inconsistent results due to
an insufficient number of patients under study.
We studied the immunological response as absolute
CD4+ T-cell count increase adjusted for CD4+ T-cell
count at baseline. First, ANCOVA model was performed
in order to assess differences between HCV Ab-positive
and HCV Ab-negative patients, stratified by anchor class
at month 24 after HAART initiation. In this analysis,
baseline CD4+ T-cell count and HCV Ab reactivity were
fixed effects. Second, ANCOVA models were used with
absolute CD4+ T-cell count increase as dependent vari-
ables to assess predictors at months 12 and 24. At this
analysis, we considered as possible predictors: age at
HAART initiation, gender, risk factors for HIV acquisi-
tion, history of AIDS diagnosis, HIV RNA, CD4+ T-cell
count, HCV Ab status, calendar year at HAART and
type of anchor class.
Additional statistical notes
Descriptive statistics were calculated for quantitative vari-
ables (mean, standard deviation – SD, median, minimum
and maximum) and qualitative variables (absolute and
percent frequencies) as appropriate. Ninety-five percent
confidence intervals (95%CI) were calculated for appropri-
ate cases. Variables were compared by means of F test
from ANOVA model or χ2 test in case of quantitative or
qualitative variables, respectively.
All analyses have been performed using the statistical
software package SAS 9.2 (SAS Inc. Cary, NC). All p value
were two-tailed and considered significant if <0.05.
Results
We studied a cohort of 3,262 patients, of whom 863
were positive for HCV Ab. Main characteristics of the
population at baseline, stratified into 6 groups by HCVAb status and type of anchor class (PI, PI/r, NNRTI), are
shown in Table 1. In the whole population males were
73%, mean age was 37.2 years at cohort entry and was
39.1 years at HAART initiation. HCV Ab-positive
patients were more likely to be younger and IVDU than
HCV Ab-negative patients; AIDS events at baseline were
more frequent in HCV Ab-negative patients.
Virological analysis (patients stratified by HCV serostatus
and classes of anchor drugs)
The early virological response rate was significantly higher
in HCV Ab-negative than in HCV Ab-positive patients.
The ITT analysis showed that, in the overall population,
87.8% patients achieved virological success. In patients re-
ceiving a PI (N= 354), those who did not reach an early
virological response were 34/146 (23.3%) among HCVAb-
positive patients versus 52/208 (25%) HCV Ab-negative
patients (p=0.66); among the 1424 patients treated with
PI/r, 44/365 (12%) HCVAb-positive versus 83/1059 (7.8%)
HCVAb-negative patients did not reach the virological re-
sponse (OR 0.612, 95%CI 0.416 to 0.903, p=0.01); in the
NNRTI group (N=1484) those who did not achieve the
virological response were 54/352 (15.3%) HCV Ab-
positive versus 130/1132 (11.5%) HCV Ab-negative
patients (OR 0.717, 95%CI 0.509 to 1.01, p= 0.06). Also at
OT analysis, significant differences between HCV Ab-
positive and HCV Ab-negative patients emerged only in
those treated with PI/r (OR 0.582, 95%CI 0.389 to 0.869,
p= 0.01), and in those treated with NNRTI (OR 0.618,
95%CI 0.419 to 0.912, p=0.02).
Figure 1 (panels “a” and “b”) shows the Kaplan-Meier
analyses in HCV Ab-negative and in HCV Ab-positive
patients for the achievement of virological suppression.
Only in patients treated with NNRTI, there was a statis-
tically significant difference for the time to achieve viro-
logical response being shorter in HCV Ab-negative
patients (log-rank p= 0.003). By contrast, no statistically
significant differences were found in patients treated
with PI and, among patients receiving PI/r, a borderline
statistical significance was found in favor of the HCV
Ab-negative group (log-rank p= 0.096).
Predictors of time to achieve virological suppression
Cox regression analysis was performed in order to explore
possible predictors of time to achieve virological suppres-
sion (Figure 2). We found that, among the baseline vari-
ables, age at HAART initiation (x 10-years older) (HR
1.109, 95%CI 1.065 to 1.155, p< 0.001), IVDU as risk fac-
tors for HIV acquisition (HR 1.344, 95%CI 1.130 to 1.599,
p= 0.001), calendar year at HAART (x 1-year more recent)
(HR 1.035, 95%CI 1.023 to 1.046, p< 0.001), were predic-
tors of shorter time to reach the virological success; in-
stead, HCV Ab-positive status (HR 0.738, 95%CI 0.652 to
0.834, p< 0.001) and higher level of HIV RNA (x1 log10
Table 1 Patients’ characteristics at baseline
Variable HCV Ab+ HCV Ab- HCV HCV Ab- HCV HCV Ab- p
PI PI Ab+ PI + r PI + r Ab +NNRTI NNRTI
(n = 146) (n = 208) (n = 365) (n = 1059) (n = 352) (n = 1132)
Males [N(%)] 112 (76.7) 148 (71.2) 284 (77.8) 751 (70.9) 257 (73.0) 829 (73.2) 0.163
Age at cohort entry, years [Mean (SD)] 34.3 (8.1) 38.3 (10) 37.2 (9.3) 38.4 (10.6) 34.3 (8.7) 37.2 (10.1) <0.001
Age at HAART initiation, years [Mean (SD)] 37.8 (6.2) 39.0 (9.6) 41.2 (7.6) 39.5 (10.4) 38.3 (7.3) 38.5 (9.9) <0.001
Calendar year at HAART [Median (range)] 2001 (2000–2009) 2001 (2000–2009) 2006 (2000–2009) 2006 (2000–2009) 2003 (2000–2009) 2004 (2000–2010)
Risk factors for HIV acquisition [N(%)]
Heterosexual 24 (16.4) 122 (58.7) 74 (20.3) 587 (55.4) 79 (22.4) 678 (59.9) <0.001
MSM 6 (4.1) 56 (26.9) 18 (4.9) 254 (24) 26 (7.4) 316 (27.9)
IVDU 110 (75.3) 10 (4.8) 228 (62.5) 21 (2) 234 (66.5) 27 (2.4)
Other/unknown 6 (4.1) 20 (9.6) 45 (12.3) 197 (18.6) 13 (3.7) 111 (9.8)
AST, IU/L [Mean (SD)] 69.3 (56.4) 44.9 (96.9) 62.1 (54.7) 32.5 (24.2) 58.0 (47.9) 34.0 (28.0) <0.001
ALT, IU/L [Mean (SD)] 68.9 (61.7) 48.2 (88.5) 70.6 (70.1) 40.9 (45.4) 64.5 (51.4) 38.9 (39.3) <0.001
Serum creatinine, mg/dL[Mean (SD)] 0.79 (0.26) 1.00 (1.35) 0.84 (0.45) 0.85 (0.43) 0.82 (0.26) 0.87 (0.64) 0.017
Cholesterolaemia, mg/dL [Mean (SD)] 138.3 (40.3) 172.0 (49.7) 150.1 (42.6) 167.1 (46.4) 156.7 (40.3) 165.1 (39.5) <0.001
Nadir of CD4+ T-cells, cells/mm3 [Mean (SD)] 143.1 (122.5) 144.8 (140.6) 169.5 (123.6) 169.5 (133.3) 179.3 (115.9) 198.5 (118.8) <0.001
AIDS diagnosis [N (%)] 43 (29.5) 76 (36.5) 95 (26.0) 314 (29.7) 67 (19.0) 215 (19.0) <0.001
CD4+ T-cell count, cells/mm3 [Mean (SD)] 222.4 (220.1) 188.3 (198.4) 210.1 (157.3) 202.5 (175.8) 239.6 (146.5) 233.8 (144.1) <0.001
HIV-1 RNA, copies/ml [Mean (SD)] 143,968 (178,492) 187,909 (192,419) 208,367 (397,492) 225,939 (529,767) 156,582 (260,891) 191,210 (543,678) 0.116
N: number, SD: standard deviation, PI/r: protease inhibitors boosted by ritonavir, PI: protease inhibitors not boosted by ritonavir NNRTI: non-nucleoside reverse transcriptase inhibitor, IVDU: intravenous drug users,





















Figure 1 Kaplan Meir analysis of time to virological response. Time to HIV-1 RNA <500 copies/ml in HCV Ab-negative patients (panel a) and
HCV Ab-positive patients (panel b) by classes of anchor drugs.
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predicted a longer time to obtained the same outcome.
Among time-dependent variables, only increasing CD4+
T-cell count was directly associated with time to achieve
the virological outcome (HR 1.057, 95%CI 1.047 to 1.066,
p< 0.001), while type of HAART was not (NNRTI versus
PI/r, p=0.75; PI versus PI/r, p=0.08; others versus PI/r,
p= 0.27).
Immunological analysis (patients stratified by HCV
serostatus and classes of anchor drugs)
For the early immunological response, achievement of
CD4+ T-cell increase ≥100/mm3 within 8 months from
HAART initiation was evaluated among patients with a
virological response. In this analysis, 2,682 patients who
had values of CD4+ T-cell count both at baseline and after
4–8 months were considered. Among patients receiving a
PI (N=239) there were not significant differences between
mono- and co-infected patients at bivariate analysis (60.8%
versus 65.5%, p=0.35). Conversely, in the PI/r group
(N=1,220) HCVAb-positive patients had a lower probabil-
ity to reach the outcome than HCV Ab-negative patientsstneitapevitagen-bAVCH
Figure 2 Predictors of time to undetectable HIV RNA (< 500 copies/m
users, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI/r: protease in
ritonavir.(62.2% versus 70.9%, OR 0.662, 95%CI 0.502 to 0.872,
p=0.003). Also, among NNRTI-receiving patients
(N=1,223), CD4+ T-cell count increase ≥100/mm3 was less
likely to be achieved by HCV Ab-positive patients (63.7%
versus 74.7%, OR 0.595, 95%CI 0.445 to 0.797, p< 0.001). A
significant difference in CD4+ T-cell count increase was
also found in this group at ANCOVA when absolute CD4+
T-cell count increase was analyzed as continuous measure
(−36.8/mm3, 95%CI −53.6 to −20.1, p< 0.001).
For the late immunological response, the absolute CD4+
T-cell count for both HCV Ab-negative and HCV Ab-
positive patients is depicted in Figure 3. By ANCOVA, at
month 24 there was a significant difference between HCV
Ab-positive and HCV Ab-negative patients with sustained
virological success in terms of absolute CD4+ T-cell count
increase both in patients treated with PI/r (mean change
[SD]: 248.4 cells/mm3 [188.6] in HCVAb-positive patients
versus 275.5 cells/mm3 [203.4] in HCV Ab-negative
patients; p=0.013) and in those treated with NNRTI con-
taining regimens (mean change [SD]: 211.1 cells/mm3
[168.3] in HCV Ab-positive patients versus 271.0 cells/
mm3 [183.4] in HCVAb-negative patients; p= 0.002).stneitapevitisop-bAVCH
l). HAART: highly active antiretroviral therapy, IVDU: intravenous drug
hibitors boosted by ritonavir, PI: protease inhibitors not boosted by
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Figure 3 Immune-recovery evaluated as absolute CD4+ T-cell count increase with respect to the baseline. Late immunological outcomes
in patients who obtained sustained HIV RNA suppression by year 1: absolute CD4+ T-cell count increase in HCV Ab-negative patients (panel a)
and in HCV Ab-positive patients (panel b). Note that for immunological analyses data were cut at month 63 when 30% of the enrolled patients
were still under observation.
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Table 2 shows the results of the ANCOVA model per-
formed to investigate possible predictors of CD4+ T-cell
recovery at different time-point of the study.
HCV Ab-positive status appeared to predict smaller
CD4+ T-cell increase after 12 months of HAART
(p= 0.005), independently from age at HAART onset,
and HIV RNA at baseline, both significant predictors of
this outcome (p= 0.002 and <0.001, respectively). How-
ever, after 24 month of HAART, the impact of HCV Ab
status disappeared.Table 2 Predictors of immune recovery (absolute CD4+ T-cell
12 months
Variable Estimate (SE)
Age at HAART initiation [x10-yrs] −13.6 (3.7)
AIDS [no vs. yes] N.S.
CD4+ [x50 cells/mm3] N.S.
HIV RNA [x1 log10] −46.8 (5.5)
HCV+ vs HCV- −38.4 (11.0)
PI vs PI/r N.S.
Results of the ANCOVA models with absolute CD4+ T-cell increase as dependent variable
statistically significant in at least one time-point are reported. Models were adjusted for a
RNA, CD4+ T-cell count, HCV Ab status, calendar year at HAART and type of treatment asDiscussion
In this study, the possible impact of HCV co-infection
on viro-immunological effectiveness of different HAART
regimens was explored both in the early and in the late
follow-up and using both a stratified and a multivariable
analysis.
In the overall population we found that 88% patients
reached HIV RNA suppression within months 4–8 months
from initiation of HAART at ITT analysis. However, per-
centages differed by HCV co-infection and by anchor class
received. In fact, HCV Ab-positive patients obtained HIVincrease from baseline after HAART)
24 months
p Estimate (SE) p






after 12 and 24 months from HAART initiation. Only variables that resulted to be
ge at HAART onset, gender, risk factors for HIV acquisition, history of AIDS, basal HIV
anchor (PI/r vs NNRTI or PI).
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patients, though this difference was greater in those treated
with PI/r (88% versus 92.2%) and NNRTI (84.7% versus
88.5%) than in those treated with PI (76.7% versus 75%). It
is possible that this finding reflects a treatment adherence
phenomenon. In fact, on one hand, if one assumes that
HCVAb-positivity is a proxy for a negative behavior related
to IVDU, with a negative influence on treatment adherence
[5,21], the difference in virological suppression would be
magnified in patients who received more complex regimens
(such as the PI/r most frequently used at the time of the
study) [22]. On the other hand, in patients prescribed less
potent regimens (such as PI), differences between the two
groups could have been diluted. Indeed, the rate of treat-
ment success in these patients was the lowest.
However, when predictors of HIV RNA response were
investigated, HCV co-infection appeared to be a negative
predictor independently from IVDU, suggesting that the
effects of these two variables were not entirely overlap-
ping. This may be due either to HCV co-infection “per se”
(probably affecting the immune control of HIV replica-
tion) or to adherence as unmeasured variable because
HCV co-infected patients may have been less adherent to
treatment even though they were not IVDU. Further bio-
psycho-social investigations are needed to understand the
complex relationship between HCV co-infection, the role
of adherence behaviors and IVDU as risk factor.
Regarding the other predictors of virological success,
the positive impact of aging (possibly reflecting better
adherence in older patients) is not new [23,24], as well
as the positive impact of more recent calendar years,
possibly reflecting a significant improvement in the drug
regimens and in the overall standard of care [25,26].
We found a positive impact of higher CD4+ T-cell count
as a protective variable for achieving HIV RNA suppres-
sion. It is possible that the immune system (either at base-
line or reconstituted by HAART) has a role in better
controlling HIV replication. If this is the case, our results
point to earlier HAART initiation as a means to preserve
immune system so that virological suppression is more fre-
quent. But also the lack of virological suppression (or viro-
logical suppression in presence of suboptimal adherence
[27]), may be a cause rather than a consequence of lower
CD4+ count, supporting the importance of a continuing as-
sessment of treatment adherence, especially in HIV/HCV
co-infected patients who appear to be disadvantaged.
Regarding the immunological outcomes, reactivity for
HCVAb was associated with a lower probability of obtain-
ing ≥100 CD4+ T-cell count increase within 8 months
from HAART initiation and with a smaller CD4+ T-cell
count recovery up to 12 months in a multivariable ana-
lysis. It has been hypothesized that CD4+ T-cell depletion
might result from ongoing cell activation and apoptosis
driven by HCV [28] and therefore HCV could lower theCD4+ T-cell recovery through a direct pathogenic effect
on lymphocytes even after HAART [29]. Our results, to-
gether with this interpretation, suggest that it is important
to treat HCV infection aimed at obtaining its eradication,
not only with the main goal of treating liver disease but
also as a means to improve the viro-immunological out-
comes of HAART, especially early upon its inception.
Greub et al. studied a group of 1596 patients (33%
of them were HCV Ab-positive) with sustained HIV
RNA <400 copies/ml and found that HCV Ab-
positive subjects had an impaired CD4+ T-cell reco-
very in the long term [10]. By contrast, data from Kauf-
mann’s studies did not show any significant difference in
CD4+ T-cell recovery when comparing HCV Ab-positive
and HCV Ab-negative patients [18]. Our results suggest
that, even though HCV infection may have an impact in
the short term (either because immune activation has not
yet been down-regulated or because HIV RNA is less
effectively controlled early upon HAART), a more pro-
longed undetectability of HIV RNA may eventually coun-
teract the apparent disadvantage occurring in HCV co-
infected patients.
The present study suffers from limitations: first, HCV
RNA was not considered, therefore patients with HCV
Ab-positive but negative HCV RNA may have been
included in the analysis, even if patients treated with anti-
HCV drugs were excluded with the aim to reduce this
possible bias. Second, HCV genotypes were not consid-
ered. A small study found that, among 171 HIV/HCV co-
infected patients, those infected by HCV genotype 3 had
inferior CD4+ T-cell increase after 12 months of follow-
up [30]. However data from Antonucci et al. [7] did not
find any correlation between HCV genotypes and
immune-reconstitution in a cohort of 284 antiretroviral
naïve patients. Therefore, further studies are needed to in-
vestigate the possible role of HCV genotypes on immune
reconstitution in larger cohorts of patients over a longer
follow-up. Third, other possible confounders such as se-
verity of liver disease were not measured. Fourth, a <500
copies/ml cut-off for undetectability was considered. It is
possible that persistent HIV replication below this cut-off
may have had an impact on immune-reconstitution but
this effect was not captured in our analysis.
In conclusion, the analysis of virological response sug-
gests that HCV Ab-positive patients need focused inter-
ventions to maximize the effectiveness of HAART,
especially early upon HAART initiation. Moreover, an
higher CD4+ T-cell count predicted better virological con-
trol suggesting that preservation of immune functions is
important not only to prevent clinical complications but
also as a means to better control HIV replication. Thus,
earlier HAART initiation is supported, especially in HIV/
HCV co-infected subjects whose viro-immunological re-
sponse may be compromised relative to HIV mono-
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tion through specific treatments is beneficial not only for
the main goal of treating liver disease but also for the
viro-immunological effectiveness of HAART.
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